Change in SciBase’s Board of Directors

As a result of his appointment as Head of Investment at Karolinska Development,
Viktor Drvota has resigned from SciBase’s Board of Directors. Alternate director
Andreas Pennervall will take his place.
Viktor Drvota moves on to Karolinska Development having been Head of Life
Science Venture at SEB Venture Capital. Viktor has been a member of SciBase’s
board since 2005. Andreas Pennervall has been an alternate director in SciBase’s
board since 2013.

Information on Viktor Drvota’s withdrawal has been submitted to the Swedish
Companies Registration Office on January 29th.

For more information, please contact:

Simon Grant, CEO

Phone: +46 72 887 43 99

Email: simon.grant@scibase.com

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm
that has developed a unique point-of-care device for the accurate detection of
malignant melanoma. Its product, Nevisense, helps doctors to detect malignant
melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig
Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden.
Nevisense is based on substantial research and has achieved excellent results in
the largest clinical study ever conducted on the detection of malignant
melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and
is awaiting FDA clearance in the United States. Nevisense is based on a method
called Electrical Impedance Spectroscopy (EIS), which uses the varying
electrical properties of human tissue to categorize cellular structures and
thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”).
Avanza is the certified advisor. Further information is available on
www.scibase.com.

SciBase Holding AB is required to disclose the information provided herein
pursuant to the Securities Markets Act and/or the Financial Instruments
Trading Act. The information was submitted for publication at 8 am on February
2, 2016.